PANBELA THERAPEUTICS, INC.
WACONIA, MN

PANBELA THERAPEUTICS, INC., originally known as Sun BioPharma, Inc., is a pioneering biopharmaceutical company focused on developing innovative therapeutics for critical unmet medical needs. The company's primary focus areas include diseases of the pancreas, such as pancreatic cancer and pancreatitis. PANBELA THERAPEUTICS collaborates with leading experts from reputable institutions including Honor Health in Scottsdale, AZ; Cedars Sinai Medical Center in Los Angeles; the University of Minnesota; Mayo Clinic Scottsdale; Austin Health Cancer Trials Centre; and Ashford Cancer Centre in Adelaide, Australia. The company is developing SBP-101, a therapeutic that targets the exocrine pancreas with precision. SBP-101 promises to ablate acinar cells as well as primary and metastatic pancreatic cancer while sparing insulin-producing islet cells and most non-pancreatic tissues, potentially reducing significant side effects associated with conventional treatments like chemotherapy, radiation, or surgery. Headquartered in Waconia, MN (formerly operating under the FEI Number 88-2805017), PANBELA THERAPEUTICS became a Florida entity marked by its registration status on June 26, 2012, and was last reinstated on October 7, 2021. The company’s mailing address is registered as 712 Vista Blvd, Waconia, MN, 55387, US. As of March 11, 2024, their latest annual report for the fiscal year 2024 was filed. The current leadership team includes Jennifer T Simpson as Chief Executive Officer and board directors D Robert Schemel and Jeffrey S Mathiesen. More information about PANBELA THERAPEUTICS can be found on its official website at sunbiopharma.com.